Nikolai Timchenko, PhD
- Head of Liver Tumor Biology, Liver Tumor Program
- Professor, UC Department of Surgery
About
Biography
Nikolai A. Timchenko, PhD, came to Cincinnati Children’s Hospital Medical Center in June of 2014 from Baylor College of Medicine (BCM), where he was a professor of pathology and was working in the Huffington Center on aging.
Dr. Timchenko obtained his PhD in the Institute of Experimental Medicine in St. Petersburg, Russia in the field of liver biology and molecular genetics. After moving to the US, Dr. Timchenko worked at BCM as an assistant professor, associate professor, and full professor until 2014.
He is currently a professor in the Division of General and Thoracic Surgery at Cincinnati Children's within the UC Department of Surgery. Dr. Timchenko is also the director of the Liver Tumor Program. He investigates mechanisms of liver cancer in children and adults, mechanisms of NAFLD, and mechanisms of age-associated diseases.
Dr. Timchenko is a member of the Digestive Health Center (Cincinnati Children's) and a professor in the Department of Surgery at the University of Cincinnati.
PhD: Institute of Experimental Medicine, St. Petersburg, Russia.
Training: Post-Doc Fellow, Department of Pathology, Baylor College of Medicine, Houston, TX.
Research Areas
General and Thoracic Surgery, Fibrosis
Publications
EZH2 is a key component of hepatoblastoma tumor cell growth. Pediatric Blood and Cancer. 2024; 71:e30774.
Genetic Ablation of C/EBPα-p300 Pathway Blocks Development of Obese Pregnancy Associated Liver Disorders in Offspring. CMGH Cellular and Molecular Gastroenterology and Hepatology. 2024; 17:347-360.
Ribonucleotide reductase subunit switching in hepatoblastoma drug response and relapse. Communications Biology. 2023; 6:249.
Therapeutic Targeting of the GSK3β-CUGBP1 Pathway in Myotonic Dystrophy. International Journal of Molecular Sciences. 2023; 24:10650.
Phosphorylation-Mediated Activation of β-Catenin-TCF4-CEGRs/ALCDs Pathway Is an Essential Event in Development of Aggressive Hepatoblastoma. Cancers. 2022; 14:6062.
β-catenin cancer-enhancing genomic regions axis is involved in the development of fibrolamellar hepatocellular carcinoma. Hepatology Communications. 2022; 6:2950-2963.
Second Generation Small Molecule Inhibitors of Gankyrin for the Treatment of Pediatric Liver Cancer. Cancers. 2022; 14:3068.
Molecular signatures of aggressive pediatric liver cancer. 2021; 2:1-4.
Olaparib Inhibits Tumor Growth of Hepatoblastoma in Patient-Derived Xenograft Models. Hepatology. 2021; 74:2201-2215.
Small Molecule Cjoc42 Improves Chemo-Sensitivity and Increases Levels of Tumor Suppressor Proteins in Hepatoblastoma Cells and in Mice by Inhibiting Oncogene Gankyrin. Frontiers in Pharmacology. 2021; 12:580722.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2024 Cincinnati Children's Hospital Medical Center. All rights reserved.
